Hengrui USA reposted this
Hengrui Pharma today announced it has entered into agreements with GSK to develop up to 12 innovative medicines, adding significant value to the globalization strategy of Hengrui and significant new growth opportunities to GSK beyond 2031. The agreements include a license for a potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for the treatment of chronic obstructive pulmonary disease. The additional 11 programs were selected to complement GSK’s extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for their potential best- or first-in class profiles. GSK will pay $500 million in upfront fees across the agreements, with a potential total value of approximately $12 billion if all programs are optioned and all development, regulatory and commercial milestones are achieved. Read the full press release: https://prn.to/454Ksl8